Recent legal changes, introduced by EA PO, allows to include national patents in the EA pharmaceutical registry (active from March 2021); however, not every member country is yet willing to submit actual information on its patents. Therefore, national registries of pharmaceutical patents are still necessary.
Russian registry is still in its prototype stage and it is expected that legal framework shall be finished soon. Yury Zubov, head of RU PTO, recently stressed a necessity of parallel registry, deriving from experience, already available in EAPO. The head of the latter, Grigory Ivliev, confirmed the EA legal base is ready and theoretically every claimant may add a national patent to EA registry. But not all national PTOs are willing to provide restricted information on the patents, so the registry is doomed to be incomplete till then.
The nation continues to break records in the realm of intellectual property. Recently, the National…
The EAPO has been actively engaging with other patent offices worldwide to establish PPH agreements,…
From March 17 to 21, a delegation from the Eurasian Patent Office (EAPO), together with…
The full-scale implementation of artificial intelligence (AI) in the ski industry is transformative. Sber has…
In 2024, the Eurasian Patent Office (EAPO) saw remarkable growth, receiving 3,252 Eurasian applications for…
As of September 18, 2024, the National Office of Intellectual Property and Innovations of Ukraine…